ELISA Kit for Anti-Epidermal Growth Factor Receptor Antibody (Anti-EGFR)

ErbB-1; ErbB1; ER1; ERB-B1; MENA; HER1; Erythroblastic Leukemia Viral(v-Erb-B)oncogene Homolog,Avian; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1

Specificity

This assay has high sensitivity and excellent specificity for detection of Anti-Epidermal Growth Factor Receptor Antibody (Anti-EGFR).
No significant cross-reactivity or interference between Anti-Epidermal Growth Factor Receptor Antibody (Anti-EGFR) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of Anti-Epidermal Growth Factor Receptor Antibody (Anti-EGFR) and the recovery rates were calculated by comparing the measured value to the expected amount of Anti-Epidermal Growth Factor Receptor Antibody (Anti-EGFR) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 81-97 85
EDTA plasma(n=5) 86-96 91
heparin plasma(n=5) 82-94 91

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Anti-Epidermal Growth Factor Receptor Antibody (Anti-EGFR) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Anti-Epidermal Growth Factor Receptor Antibody (Anti-EGFR) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Anti-Epidermal Growth Factor Receptor Antibody (Anti-EGFR) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 79-98% 90-103% 82-101% 96-103%
EDTA plasma(n=5) 94-105% 97-105% 93-101% 78-96%
heparin plasma(n=5) 78-97% 88-95% 93-105% 91-101%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
TMB Substrate 1×9mL Stop Solution 1×6mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 5 times;
5. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
6. Add 50µL Stop Solution. Read at 450nm immediately.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Thoracic Cancer Nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced non-small-cell lung cancer Wiley: source
J Cent Nerv Syst Dis.? Increased Epidermal Growth Factor Receptor (EGFR) Associated with Hepatocyte Growth Factor (HGF) and Symptom Severity in Children with Autism … Pubmed:25249767
Mol Cancer Ther GC1118, an anti-EGFR antibody with a distinct binding epitope and superior inhibitory activity against high-affinity EGFR ligands PubMed: 26586721
Cell Death Dis.  LINC01225 promotes occurrence and metastasis of hepatocellular carcinoma in an epidermal growth factor receptor-dependent pathway Pubmed:26938303
analytica chimica acta Microfluidic immunosensor based on mesoporous silica platform and CMK-3/poly-acrylamide-co-methacrylate of dihydrolipoic acid modified gold electrode for cancer biomarker detection. pubmed:28335979
Talanta EGFR detection in extracellular vesicles of breast cancer patients through immunosensor based on silica-chitosan nanoplatform Doi: 10.1016/j.talanta.2018.10.016
Bioorganic Chemistry Design, synthesis, molecular docking and biological activity evaluation of some novel indole derivatives as potent anticancer active agents and apoptosis inducers Pubmed: 30665034
Journal of enzyme inhibition and medicinal chemistry Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile Pubmed: 30919701
Bioorganic Chemistry Design and synthesis of new benzoxazole/benzothiazole-phthalimide hybrids as antitumor-apoptotic agents
Bioorganic Chemistry Synthesis and anticancer activity of bis-benzo [d][1, 3] dioxol-5-yl thiourea derivatives with molecular docking study Pubmed: 31288134
Oxidative Medicine and Cellular Longevity Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters … Pubmed: 31737175
Neoplasia Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine Pubmed: 33212364
Association between Serum Epidermal Growth Factor Receptor and Cyclooxygenase-2 Levels in Patients with Non-small Cell Carcinoma of Lung
Synthesis, EGFR-TK inhibition and anticancer activity of new quinoxaline derivatives
IMMUNOLOGIC RESEARCH Humoral immune response to epidermal growth factor receptor in lung cancer 33495907
European Journal of Medicinal Chemistry Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure¨Cactivity relationship and biological activity as potential antitumor and anticonvulsant agents 33545637
Journal of Molecular Structure Design, synthesis, antiproliferative evaluation, and molecular docking study of new quinoxaline derivatives as apoptotic inducers and EGFR inhibitors
ACS Appl Mater Interfaces Emitter–Quencher Pair of Single Atomic Co Sites and Monolayer Titanium Carbide MXenes for Luminol Chemiluminescent Reactions 34914377
Bioorganic Chemistry Discovery of new pyrimido [5, 4-c] quinolines as potential antiproliferative agents with multitarget actions: Rapid synthesis, docking, and ADME studies Pubmed:35219045
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPA757Hu01 Recombinant Epidermal Growth Factor Receptor (EGFR) Positive Control; Immunogen; SDS-PAGE; WB.
APA757Hu61 Active Epidermal Growth Factor Receptor (EGFR) Cell culture; Activity Assays.
EPA757Hu62 Eukaryotic Epidermal Growth Factor Receptor (EGFR) Positive Control; Immunogen; SDS-PAGE; WB.
RPA757Hu02 Recombinant Epidermal Growth Factor Receptor (EGFR) Positive Control; Immunogen; SDS-PAGE; WB.
EPA757Hu61 Eukaryotic Epidermal Growth Factor Receptor (EGFR) Positive Control; Immunogen; SDS-PAGE; WB.
PAA757Hu06 Polyclonal Antibody to Epidermal Growth Factor Receptor (EGFR) WB; IHC; ICC; IP.
PAA757Hu02 Polyclonal Antibody to Epidermal Growth Factor Receptor (EGFR) WB; IHC; ICC; IP.
PAA757Hu01 Polyclonal Antibody to Epidermal Growth Factor Receptor (EGFR) WB; IHC; ICC; IP.
FAA757Hu51 APC-Linked Anti-Epidermal Growth Factor Receptor (EGFR) Polyclonal Antibody FCM
MAA757Hu27 Monoclonal Antibody to Epidermal Growth Factor Receptor (EGFR) WB; IHC; ICC; IP.
MAA757Hu29 Monoclonal Antibody to Epidermal Growth Factor Receptor (EGFR) WB; IHC; ICC; IP.
RAA757Hu21 Recombinant Antibody to Epidermal Growth Factor Receptor (EGFR) WB; IF; ICC; IHC; IP; FCM.
MAA757Hu21 Monoclonal Antibody to Epidermal Growth Factor Receptor (EGFR) WB; IHC; ICC; IP.
MAA757Hu23 Monoclonal Antibody to Epidermal Growth Factor Receptor (EGFR) WB; IHC; ICC; IP.
MAA757Hu24 Monoclonal Antibody to Epidermal Growth Factor Receptor (EGFR) WB; IHC; ICC; IP.
MAA757Hu25 Monoclonal Antibody to Epidermal Growth Factor Receptor (EGFR) WB; IHC; ICC; IP.
MAA757Hu22 Monoclonal Antibody to Epidermal Growth Factor Receptor (EGFR) WB; IHC
SEA757Hu ELISA Kit for Epidermal Growth Factor Receptor (EGFR) Enzyme-linked immunosorbent assay for Antigen Detection.
HEA757Hu High Sensitive ELISA Kit for Epidermal Growth Factor Receptor (EGFR) Enzyme-linked immunosorbent assay for Antigen Detection.
AEA757Hu ELISA Kit for Anti-Epidermal Growth Factor Receptor Antibody (Anti-EGFR) Enzyme-linked immunosorbent assay for Antibody Detection.
LMA757Hu Multiplex Assay Kit for Epidermal Growth Factor Receptor (EGFR) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.